Unassociated Document
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act 1934
Date of
Report (date of earliest event reported): January 1, 2010
JIANGBO
PHARMACEUTICALS, INC.
(Exact
name of registrant as specified in charter)
Florida
(State or
other jurisdiction of incorporation)
|
000-53037
|
|
65-1130026
|
|
(Commission
File Number)
|
|
(IRS
Employer Identification
No.)
|
|
25
Haibe Road, Laiyang Economic Development Zone
|
|
Laiyang
City, Yantai, Shandong Province, People’s Republic of China
26520
|
(Address of principal executive offices and zip code)
(Registrant's
telephone number including area code)
(Registrant's
former name or former address, if changed since last report)
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of registrant under any of the following
provisions:
¨ Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
¨ Soliciting
material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR
240.14a-12(b))
¨ Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
¨ Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Item
4.01. Changes in Registrant’s Certifying Accountant.
Jiangbo
Pharmaceuticals, Inc., a Florida corporation (the “Company”) was notified that,
effective January 1, 2010, certain partners of Moore Stephens Wurth Frazer and
Torbet, LLP (“MSWFT”) and Frost, PLLC (“Frost”) formed Frazer Frost, LLP
(“Frazer Frost”), a new partnership. Pursuant to the terms of a combination
agreement by and among MSWFT, Frazer Frost and Frost, each of MSWFT and Frost
contributed substantially all of their assets and certain of their liabilities
to Frazer Frost, resulting in Frazer Frost assuming MSWFT’s engagement letter
with the Company and becoming the Company’s new independent accounting
firm. Frazer Frost is currently registered with the Public
Company Accounting and Oversight Board (“PCAOB”).
The audit
reports of MSWFT on the financial statements of the Company as of and for the
years ended June 30, 2009 and June 30, 2008 did not contain an adverse opinion
or a disclaimer of opinion, and were not qualified or modified as to
uncertainty, audit scope or accounting principles.
During
the Company’s most two recent fiscal years ended June 30, 2009 and 2008 and
through January 1, 2010, the Company did not consult with Frazer Frost on
(i) the application of accounting principles to a specified transaction,
either completed or proposed, or the type of audit opinion that may be rendered
on the Company’s financial statements, and Frazer Frost did not provide either a
written report or oral advice to the Company that was an important factor
considered by the Company in reaching a decision as to any accounting, auditing,
or financial reporting issue; or (ii) the subject of any disagreement, as
defined in Item 304 (a)(1)(iv) of Regulation S-K and the related
instructions, or a reportable event within the meaning set forth in
Item 304(a)(1)(v) of Regulation S-K.
In
connection with the audits of the Company’s financial statements for the fiscal
year ended June 30, 2009 and 2008 and through the date of this Current Report,
there were: (i) no disagreements between the Company and MSWFT on any
matters of accounting principles or practices, financial statement disclosure,
or auditing scope or procedures, which disagreements, if not resolved to the
satisfaction of MSWFT, would have caused MSWFT to make reference to the subject
matter of the disagreement in their reports on the Company’s financial
statements for such years, and (ii) no reportable events within the meaning set
forth in Item 304(a)(1)(v) of Regulation S-K.
The
Company has provided MSWFT a copy of the disclosures in this Form 8-K and has
requested that MSWFT furnish it with a letter addressed to the Securities and
Exchange Commission stating whether or not MSWFT agrees with the Company’s
statements in this Item 4.01(a). A copy of the letter dated January 7,
2010, furnished by MSWFT in response to that request is filed as
Exhibit 16.1 to this Form 8-K.
Item 9.01. Financial
Statements and Exhibits.
|
16.1
|
Letter
of Moore Stephens Wurth Frazer and Torbet, LLP dated January 7,
2010
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
|
JIANGBO
PHARMACEUTICALS, INC.
|
| |
|
|
|
By:
|
/s/ Cao Wubo
|
|
|
|
Name:
Cao Wubo
|
|
|
|
Title:
Chief Executive
Officer
|
Dated:
January 7, 2010